CLEVELAND, Ohio, July 8, 2025 – MediView XR, Inc., a leader in medical imaging technology, today announced the enrollment of the first patient in a clinical study evaluating the efficacy of the XR90 Holographic Surgical Navigation System for percutaneous tumor biopsies. The study, titled “Clinical Evaluation of an Intra-procedural 3D Needle Guidance Platform for Performing Percutaneous Soft Tissue Tumor Biopsy as an Adjunct to Standard Image Guidance,” is being conducted in collaboration with leading institutions including NewYork-Presbyterian/Weill Cornell Medical Center, MedStar Georgetown University Hospital, and MedStar Washington Hospital Center.
The multicenter study, which has received IRB approval, plans to enroll 104 patients over the next 24 months. The goal is to evaluate the procedural efficiency of the XR90 system as an adjunct to standard imaging techniques such as ultrasound and CT, compared to standard imaging alone. The investigation aims to further quantify the benefits and value of the FDA-cleared (K223125) XR90 augmented reality platform.
“We are thrilled to partner with leading healthcare institutions on this significant study,” said Mina Fahim, CEO of MediView. “Our mission is to provide physicians with tools that enhance their workflow and optimize patient care. We are excited to see how the XR90 system can simplify procedures and support interventional radiology.”
The XR90 system provides intuitive 3D visualization, enabling physicians to see “through” the patient by displaying real-time internal anatomy, including bones, tissues, organs, and vessels. It complements standard imaging techniques and is designed to increase precision and efficiency in minimally invasive procedures.
MediView, a Cleveland-based medical technology company, collaborates with partners such as GE Healthcare and Microsoft to advance its augmented reality technologies and democratize access to advanced medical imaging.
For more information: www.mediview.com
The study marks a significant step in the advancement of augmented reality technologies for medicine and has the potential to transform standards in interventional radiology.
